Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research. The initiative between the diabetes software developer and smart ring maker aims to create a comprehensive, multi-modal, real-world dataset for diabetes, utilizing Tidepool’s diabetes device data paired with biometric data collected by the leading Oura Ring Gen 3. This […]
Clinical Trials
Boston Scientific shares positive Agent drug-coated balloon findings
Boston Scientific (NYSE: BSX) today shared findings from new analyses of its Agent drug-coated balloon (DCB). Agent serves as an alternative to traditional therapies like balloon angioplasty, additional layers of stenting or radiation. The paclitaxel-coated balloon transfers a therapeutic dose of drug to the vessel wall, helping to prevent in-stent restenosis (ISR) reoccurrence. The FDA […]
Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial
Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB). The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon. Agent is currently the only FDA-approved drug-coated balloon (DCB) for coronary indication, picking up approval in March. New Hope, […]
Multiple studies back Cordis Selution SLR drug-eluting balloon
Cordis today announced new findings from a duo of studies supporting the use of its Selution SLR drug-eluting balloon (DEB) system. Miami Lakes, Florida-based Cordis announced results from the SELUTION DeNovo and SELUTION 4ISR trials at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. Both randomized clinical trials demonstrated positive outcomes that met […]
SiBionics reports strong CGM, ketone monitoring data
SiBionics announced the presentation of new data supporting its continuous glucose monitoring (CGM) and ketone monitoring (CKM) devices. The China-based company shared findings for its integrated CGM and CKM diabetes management solution as well. It showcased the technology at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria. […]
Tandem reports positive outcomes for automated insulin delivery in type 2 regardless of C-peptide levels
Tandem Diabetes Care (Nasdaq:TNDM) today announced study findings highlighting the benefits of its automated insulin delivery system. Findings from the “Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level” study were published in the American Diabetes Association’s Diabetes Care. The study, a sub-analysis from the 2IQP trial, found that Control-IQ+ automated […]
Modular Medical can start insulin patch pump feasibility study
Modular Medical (Nasdaq:MODD) announced that it received Institutional Review Board (IRB) approval to study its next-generation insulin pump. San Diego-based Modular Medical can now conduct an in-house feasibility study for its next-generation Pivot insulin delivery system. The company plans for the study of the new pump to use sterile saline. Modular Medical unveiled Pivot, its […]
Medtronic reports positive 3-year automated insulin delivery data
Medtronic (NYSE:MDT) today shared three-year real-world evidence highlighting improvements with its MiniMed 780G automated insulin delivery system. MiniMed 780G, the company’s latest-generation AID system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs. Data demonstrated rapid, sustained […]
Dexcom to unveil new basal insulin titration module under FDA review, reports positive CGM data
Dexcom (Nasdaq:DXCM) today announced plans to unveil its Smart Basal integrated titration module for insulin delivery. The company plans to unveil Smart Basal and present new continuous glucose monitor (CGM) data at the 61st annual European Association for the Study of Diabetes (EASD) Conference in Vienna, Austria, this week. Dexcom’s CTO Girish Naganathan will speak […]
Teleflex enrolls first patient in dual-drug-eluting device study of coronary interventions for diabetes
Teleflex (NYSE:TFX) announced today that it enrolled the first patient in its DUBSTENT DIABETES trial. The randomized, investigator-initiated trial evaluates a dual-device strategy for percutaneous coronary intervention (PCI) in patients with diabetes mellitus. DUBSTENT DIABETES investigates the safety and efficacy of combining drug-coated balloon (DCB) angioplasty with drug-eluting stent (DES) implantation compared to single-device strategies […]
